Literature DB >> 18465316

Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.

Mogens Blichert-Toft1, Peer Christiansen, Henning T Mouridsen.   

Abstract

DBCG (Danish Breast Cancer Cooperative Group) constitutes a multidisciplinary organization established in 1975 by the Danish Surgical Society. The purpose involves first and foremost a nation-wide standardization of breast cancer treatment based on novel therapeutic principles, collaboration between experts handling diagnostic work-up, surgery, radiotherapy, medical oncology, and basic research, and, further, complete registration of relevant clinical data in a national data base attached to DBCG. Data are processed by the Secretariat personnel composed of statisticians, data managers, and data secretaries making current analyses of outcome results feasible. DBCG is run by the Executive Committee consisting of expert members appointed by their respective society. From 1978 the DBCG project gained widely accession from participating units, and since then nearly all newly diagnosed breast cancer incident cases are reported and registered in the national data base. Today, the data base includes approximately 80 000 incidents of primary breast cancer. Annually, the Secretariat receives roughly 1.5 million parameters to be entered into the data base. Over time DBCG has generated seven treatment programmes including in situ lesions and primary invasive breast cancer. Probands are subdivided into risk groups based on a given risk pattern and allocated to various treatment programmes accordingly. The scientific initiatives are conducted in the form of register- and cohort analysis or randomized trials in national or international protocolized settings. Yearly, about 4 000 new incident cases of primary invasive breast cancer and about 200 in situ lesions enter the national programmes. Further, about 600 women with hereditary disposition of breast cancer are registered and evaluated on a risk scale. The main achievements resulted in a reduction of relative risk of death amounting up to 20% and increased 5-year overall survival ascending from 60% to roughly 80%. This article is partly based on a Danish paper to be published in the Centenary Jubilee book of the Danish Surgical Society, 2008.

Entities:  

Mesh:

Year:  2008        PMID: 18465316     DOI: 10.1080/02841860802068615

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  21 in total

1.  Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.

Authors:  Thomas P Ahern; Per Damkier; Søren Feddersen; Anders Kjærsgaard; Timothy L Lash; Stephen Hamilton-Dutoit; Cathrine Bredal Lythjohan; Bent Ejlertsen; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Acta Oncol       Date:  2020-04-30       Impact factor: 4.089

2.  Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Håvard Søiland; Jennifer Gjerde; Jens Peter Garne; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

3.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

4.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

5.  Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Authors:  Thomas P Ahern; Deirdre P Cronin-Fenton; Timothy L Lash; Henrik Toft Sørensen; Anne Gulbech Ording; Stephen J Hamilton-Dutoit; Ylva Hellberg
Journal:  Acta Oncol       Date:  2016-04-08       Impact factor: 4.089

6.  Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Stephen Hamilton-Dutoit; Jens Peter Garne; Marianne Ewertz; Henrik Toft Sørensen; Lars Pedersen
Journal:  Acta Oncol       Date:  2010-04       Impact factor: 4.089

7.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

8.  Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark.

Authors:  William F Anderson; Philip S Rosenberg; Lucia Petito; Hormuzd A Katki; Bent Ejlertsen; Marianne Ewertz; Birgitte B Rasmussen; Maj-Britt Jensen; Niels Kroman
Journal:  Int J Cancer       Date:  2013-06-13       Impact factor: 7.396

9.  Risk of Parkinson's disease after tamoxifen treatment.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  BMC Neurol       Date:  2010-04-12       Impact factor: 2.474

10.  No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.

Authors:  Thomas P Ahern; Lars Pedersen; Deirdre P Cronin-Fenton; Henrik Toft Sørensen; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.